<mods:mods xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" version="3.3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mods="http://www.loc.gov/mods/v3"><mods:titleInfo><mods:title>PHARMACOLOGY OF HYPOGLYCEMIC DRUGS</mods:title></mods:titleInfo><mods:name type="personal"><mods:namePart type="given">Rustamov Shoxrizod Nuroli o‘g‘li</mods:namePart><mods:namePart type="family">Rustamov Shoxrizod Nuroli o‘g‘li</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">Asfandiyorov Javodbek Mirzaali o‘g‘li</mods:namePart><mods:namePart type="family">Asfandiyorov Javodbek Mirzaali o‘g‘li</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">Odilov Ramziddin Dilshodovich</mods:namePart><mods:namePart type="family">Odilov Ramziddin Dilshodovich</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:abstract>Current drugs for the treatment of type 2 diabetes mellitus have different molecular targets and different mechanisms of action. The use of these drugs in the form of monotherapy and combination therapy makes it possible to achieve reliable disease control. However, the rational choice of a pharmacotherapy strategy for type 2 diabetes mellitus is a difficult problem in clinical practice. The article discusses some aspects of this problem.</mods:abstract><mods:originInfo><mods:dateIssued encoding="iso8601">2024-02-29</mods:dateIssued></mods:originInfo><mods:genre>Maqola</mods:genre></mods:mods>